Literature DB >> 22227213

Identification of novel SAR properties of the Jak2 small molecule inhibitor G6: significance of the para-hydroxyl orientation.

Rebekah Baskin1, Meghanath Gali, Sung O Park, Zhizhuang Joe Zhao, György M Keseru, Kirpal S Bisht, Peter P Sayeski.   

Abstract

In this study, we analyzed the structure-activity relationship properties of the small molecule Jak2 inhibitor G6. We synthesized a set of derivatives containing the native para-hydroxyl structure or an alternative meta-hydroxyl structure and examined their Jak2 inhibitory properties. We found that the para-hydroxyl derivative known as NB15 had excellent Jak2 inhibitory properties in silico, in vitro, and ex vivo when compared with meta-hydroxyl derivatives. These results indicate that NB15 is a potent derivative of the Jak2 inhibitor G6, and that maintaining the para-hydroxyl orientation of G6 is critical for its Jak2 inhibitory potential.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22227213      PMCID: PMC3267892          DOI: 10.1016/j.bmcl.2011.12.042

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  28 in total

1.  Jak2 is essential for signaling through a variety of cytokine receptors.

Authors:  E Parganas; D Wang; D Stravopodis; D J Topham; J C Marine; S Teglund; E F Vanin; S Bodner; O R Colamonici; J M van Deursen; G Grosveld; J N Ihle
Journal:  Cell       Date:  1998-05-01       Impact factor: 41.582

Review 2.  Mitosis in transition.

Authors:  R W King; P K Jackson; M W Kirschner
Journal:  Cell       Date:  1994-11-18       Impact factor: 41.582

3.  The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.

Authors:  Annet Kirabo; Sung O Park; Anurima Majumder; Meghanath Gali; Mary K Reinhard; Heather L Wamsley; Zhizhuang Joe Zhao; Christopher R Cogle; Kirpal S Bisht; György M Keserü; Peter P Sayeski
Journal:  Neoplasia       Date:  2011-11       Impact factor: 5.715

4.  Bcr/Abl activates transcription of the Bcl-X gene through STAT5.

Authors:  F Gesbert; J D Griffin
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

5.  STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells.

Authors:  T Nosaka; T Kawashima; K Misawa; K Ikuta; A L Mui; T Kitamura
Journal:  EMBO J       Date:  1999-09-01       Impact factor: 11.598

6.  The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases.

Authors:  M Sattler; M A Durstin; D A Frank; K Okuda; K Kaushansky; R Salgia; J D Griffin
Journal:  Exp Hematol       Date:  1995-08       Impact factor: 3.084

7.  Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death.

Authors:  A Gross; X M Yin; K Wang; M C Wei; J Jockel; C Milliman; H Erdjument-Bromage; P Tempst; S J Korsmeyer
Journal:  J Biol Chem       Date:  1999-01-08       Impact factor: 5.157

8.  Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase.

Authors:  L S Argetsinger; G S Campbell; X Yang; B A Witthuhn; O Silvennoinen; J N Ihle; C Carter-Su
Journal:  Cell       Date:  1993-07-30       Impact factor: 41.582

9.  JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin.

Authors:  B A Witthuhn; F W Quelle; O Silvennoinen; T Yi; B Tang; O Miura; J N Ihle
Journal:  Cell       Date:  1993-07-30       Impact factor: 41.582

10.  Synergistic action of Drosophila cyclins A and B during the G2-M transition.

Authors:  J A Knoblich; C F Lehner
Journal:  EMBO J       Date:  1993-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.